Smith & Nephew (OTCPK:SNNU.F) - Aandelenkoers, Nieuws & Analyse

SNNU.F Overzicht aandelen

Smith & Nephew plc ontwikkelt, produceert, verkoopt en verhandelt samen met haar dochterondernemingen medische hulpmiddelen en diensten in het Verenigd Koninkrijk en internationaal. Meer informatie

SNNU.F fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	3/6
Prestaties in het verleden	3/6
Financiële gezondheid	4/6
Dividenden	3/6

Beloningen

Verhandeld tegen 38.4% onder onze schatting van de reële waarde

De winst zal naar verwachting met 22.55% per jaar groeien

De winst groeide het afgelopen jaar met 39.9%

Analisten zijn het erover eens dat de aandelenkoers met 29.8% zal stijgen

Risicoanalyse

Het dividend van 3.03% wordt niet goed gedekt door de winst of de vrije kasstromen

Aandelen zijn zeer illiquide

Heeft een hoog schuldenniveau

Grote eenmalige posten die de financiële resultaten beïnvloeden

Smith & Nephew plc Concurrenten

Teleflex

NYSE:TFX

US$8.9b

Baxter International

NYSE:BAX

US$17.0b

Masimo

NasdaqGS:MASI

US$9.3b

Zimmer Biomet Holdings

NYSE:ZBH

US$21.9b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Smith & Nephew
Historische aandelenkoersen
Huidige aandelenkoers	UK£12.25
52 Week Hoogtepunt	UK£15.70
52 Week Laag	UK£11.49
Bèta	0.70
11 maand verandering	-14.63%
3 maanden verandering	-18.33%
1 Jaar Verandering	-7.69%
33 jaar verandering	-24.29%
5 jaar verandering	-45.37%
Verandering sinds IPO	105.88%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	SNNU.F	US Medical Equipment	US Markt
7D	0.6%	1.5%	2.2%
1Y	-7.7%	20.8%	31.6%

Rendement versus industrie: SNNU.F presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van 20.8 % opleverde.

Rendement versus markt: SNNU.F presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.6 % opleverde.

Prijsvolatiliteit

Is SNNU.F's price volatile compared to industry and market?
SNNU.F volatility
SNNU.F Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	8.1%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van SNNU.F is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van SNNU.F in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1856	18,000	Deepak Nath	www.smith-nephew.com

Smith & Nephew plc ontwikkelt, produceert, verkoopt en verhandelt, samen met haar dochterondernemingen, medische hulpmiddelen en diensten in het Verenigd Koninkrijk en internationaal. Het bedrijf is actief in drie segmenten: Orthopedie, Sportgeneeskunde & KNO, en Advanced Wound Management. Het bedrijf biedt knie-implantaatproducten voor knievervangingsprocedures; heupimplantaten voor revisieprocedures; trauma- en extremiteitsproducten waaronder interne en externe hulpmiddelen voor de stabilisatie van ernstige fracturen en misvormingscorrectieprocedures; en andere reconstructieproducten.

Smith & Nephew plc Samenvatting

Hoe verhouden de winst en inkomsten van Smith & Nephew zich tot de beurswaarde?
SNNU.F fundamentele statistieken
Marktkapitalisatie	US$10.78b
Inkomsten(TTM)	US$305.00m
Inkomsten(TTM)	US$5.64b

35.4x

Koers/Winstverhouding

1.9x

P/S-verhouding

Is SNNU.F overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SNNU.F resultatenrekening (TTM)
Inkomsten	US$5.64b
Kosten van inkomsten	US$1.67b
Brutowinst	US$3.97b
Overige uitgaven	US$3.66b
Inkomsten	US$305.00m

Laatst gerapporteerde inkomsten

Jun 29, 2024

Volgende inkomensdatum

Feb 25, 2025

Winst per aandeel (EPS)	0.35
Brutomarge	70.33%
Nettowinstmarge	5.41%
Schuld/Eigen Vermogen Verhouding	66.7%

Hoe presteerde SNNU.F op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

3.0%

Huidig dividendrendement

107%

Uitbetalingsratio

SNNU.F Overzicht aandelen

Beloningen

Risicoanalyse

Smith & Nephew plc Concurrenten

NYSE:TFX

US$8.9b

NYSE:BAX

US$17.0b

NasdaqGS:MASI

US$9.3b

NYSE:ZBH

US$21.9b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Smith & Nephew plc Provides Earnings Guidance for the Full Year 2024 and for 2025

Smith & Nephew plc to Report Fiscal Year 2024 Results on Feb 25, 2025

Smith+Nephew Announces LEGION Hinged Knee System Now Available in the United States with Proprietary OXINIUM (Oxidized Zirconium)

Smith+Nephew Announces Board and Committee Changes

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Reaffirms Earnings Guidance for the Year 2024

Smith+Nephew Announces 510(K) Clearance of New Catalysystem Primary Hip System

Recent updates

Smith & Nephew plc Provides Earnings Guidance for the Full Year 2024 and for 2025

Smith & Nephew plc to Report Fiscal Year 2024 Results on Feb 25, 2025

Smith+Nephew Announces LEGION Hinged Knee System Now Available in the United States with Proprietary OXINIUM (Oxidized Zirconium)

Smith+Nephew Announces Board and Committee Changes

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Reaffirms Earnings Guidance for the Year 2024

Smith+Nephew Announces 510(K) Clearance of New Catalysystem Primary Hip System

Cevian Capital II GP Limited acquired 5.02% stake in Smith & Nephew plc (LSE:SN.).

Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024

Smith & Nephew plc to Report First Half, 2024 Results on Aug 01, 2024

Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy System

Smith & Nephew plc Announces Board Changes

Smith & Nephew plc, Annual General Meeting, May 01, 2024

Smith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024

Smith+Nephew Announces Commercial Launch of Its Aetos Shoulder System for Anatomic and Reverse Shoulder Replacement At Aaos 2024 Annual Meeting

Smith & Nephew plc Announces Standout Results for Its Regeneten Bioinductive Implant from A Recently Completed Randomized Controlled Trial

Smith & Nephew plc (LSE:SN.) acquired CartiHeal (2009) Ltd.

Smith+Nephew Announces Board Changes

Smith+Nephew Announces Board Changes

Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million.

Smith & Nephew plc Provides Earning Guidance for Full Year 2023

Smith & Nephew plc Announces Appointment of John Rogers as CFO

Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023

Smith & Nephew plc Announces Board and Committee Changes

Smith & Nephew plc Increases Revenue Guidance for 2023

Smith & Nephew plc Announces Step Down of Anne-Françoise Nesmes as Chief Financial Officer

Smith+Nephew Announces 510(K) Clearance of its AETOS Shoulder System

Smith & Nephew plc, Annual General Meeting, Apr 26, 2023

Smith & Nephew plc to Report Fiscal Year 2022 Results on Feb 21, 2023

Smith & Nephew plc Announces Revenue Guidance for 2022

Smith+Nephew Expands Procedural Innovation with Introduction of JOURNEY(TM) II ROX(TM) Total Knee Solution

Smith+Nephew First to Market with Revision Knee Indication on Robotics Platform

Smith+Nephew Launches OR3O ™ Dual Mobility System in Japan for Use in Primary and Revision Hip Arthroplasty

Smith+Nephew Announces New Data Furthering a Number of Published Studies Supporting the Use of Its REGENETEN Bioinductive Implant in Rotator Cuff Repair

Smith & Nephew plc to Report Q2, 2023 Results on Aug 03, 2023

Smith & Nephew plc Announces Executive Changes

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Full Year of 2022

Smith+Nephew Launches Clinical Support App to Help Reduce Practice Variation in Wound Care

Smith & Nephew plc Announces Executive Changes

Smith & Nephew plc Announces Executive Changes

Smith+Nephew Announces First Total Hip Replacement Cases on its CORI Surgical System Using RI.HIP Modeler and RI.HIP Navigation

Smith+Nephew Announces New Study Showing GRAFIX™ Membrane Cut the Rate of Diabetic Foot Ulcer Recurrence in Half Compared to Leading Competitors

Smith & Nephew plc, Annual General Meeting, Apr 13, 2022

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Year of 2022

Smith+Nephew Expands Next-Generation Handheld Robotic-Assisted CORI™ Surgical System into Total Hip Arthroplasty with RI.HIP NAVIGATION

Smith+Nephew Announces New Indications for Use for its PICO 7 and PICO 14 Single Use Negative Pressure Wound Therapy Systems

Smith & Nephew plc (LSE:SN.) acquired Engage Surgical.

Smith & Nephew plc (LSE:SN.) announces an Equity Buyback for $300 million worth of its shares.

Smith+Nephew Launches Real Intelligence and CORI Surgical System and Next Generation Handheld Robotics Platform in Canada

Smith+Nephew Launches CORI Handheld Robotics

Smith+Nephew Introduces Pioneering New Technologies for Its Journey II Total Knee Arthroplasty Portfolio

Smith+Nephew Announces Launch of WEREWOLF FASTSEAL 6.0 Hemostasis Wand

Smith+Nephew Announces Study Results Showing Patients Treated with Just its REGENETEN Bioinductive Implant for Partial-Thickness Rotator Cuff Tears

Smith+Nephew Launches ARIA Home PT, a Remote Physical Therapy Solution

Smith & Nephew plc Provides Revenue Guidance for the Full Year 2021

Smith+Nephew's ALLEVYN™ LIFE Foam Dressings Halved Change Frequency, Significantly Reduced Cost and Improved Treatment Satisfaction in Real-World Study

Net Health Adds Smith+Nephew's RENASYS GO Negative Pressure Wound Therapy System to Net Health® Wound Care Connections Lineup

Smith & Nephew plc, Annual General Meeting, Apr 14, 2021

Smith & Nephew plc Announces Appointment of John Ma as Non-Executive Director, Effective 17 February 2021

Smith+Nephew Partners with Movemedical to Streamline Inventory Management and Improve Customer Experience